PP
ACAD icon

Paloma Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Paloma Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,569
Closed -$512K – 1986
2020
Q4 		$512K Buy
+9,569
New +$475K 0.01% 901
2020
Q3 		– Sell
-252,100
Closed -$12.2M – 2015
2020
Q2 		$12.2M Buy
+252,100
New +$12.1M 0.21% 77
2020
Q1 		– Sell
-10,883
Closed -$466K – 1175
2019
Q4 		$466K Buy
+10,883
New +$473K 0.01% 1445
2019
Q3 		– Sell
-25,673
Closed -$686K – 1901
2019
Q2 		$686K Sell
25,673
-16,854
-40% -$431K 0.01% 870
2019
Q1 		$1.14M Buy
42,527
+14,339
+51% +$335K 0.03% 664
2018
Q4 		$456K Buy
+28,188
New +$547K 0.01% 706
2017
Q4 		– Sell
-18,200
Closed -$686K – 1834
2017
Q3 		$686K Buy
+18,200
New +$592K 0.01% 1363
2017
Q2 		– Sell
-21,125
Closed -$726K – 2119
2017
Q1 		$726K Buy
+21,125
New +$746K 0.01% 1430
2016
Q4 		– Sell
-28,636
Closed -$911K – 1948
2016
Q3 		$911K Sell
28,636
-110,746
-79% -$3.75M 0.01% 1091
2016
Q2 		$4.52M Buy
+139,382
New +$4.66M 0.05% 298
2016
Q1 		– Sell
-6,449
Closed -$229K – 1825
2015
Q4 		$229K Buy
+6,449
New +$227K 0.01% 1482
2015
Q3 		– Sell
-7,400
Closed -$310K – 1573
2015
Q2 		$310K Buy
+7,400
New +$286K 0.01% 1314
2014
Q4 		– Sell
-11,650
Closed -$288K – 1131
2014
Q3 		$288K Sell
11,650
-12,679
-52% -$297K 0.01% 730
2014
Q2 		$550K Buy
+24,329
New +$508K 0.02% 543

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Paloma Partners's ACAD Position: Q1 2021 in Review

Paloma Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 9,569 shares — an estimated $512K sold.

Paloma Partners first reported a position in ACAD in Q2 2014 and held it in 14 quarters. The position peaked at $12.2M in Q2 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Paloma Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Paloma Partners sold 9,569 Acadia Pharmaceuticals shares in Q1 2021, an estimated $512K.
  • Paloma Partners first reported a position in Acadia Pharmaceuticals in Q2 2014 and held it in 14 quarters.
  • Paloma Partners's Acadia Pharmaceuticals position peaked at $12.2M in Q2 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.